XKRX
019170
Market cap376mUSD
Oct 08, Last price
9,780.00KRW
1D
-11.17%
1Q
20.74%
Jan 2017
64.37%
Name
Shinpoong Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shinpoong Pharmaceutical Co., Ltd., a South Korean firm, specializes in the production and distribution of a broad spectrum of pharmaceutical goods. Its product offerings span various therapeutic categories, including cephalosporin and penicillin antibiotics, as well as a range of finished drug formulations. The company further supplies active pharmaceutical ingredients (APIs) and specialized medications like Pyramax, an anti-malarial treatment. Additionally, Shinpoong develops drugs for conditions such as hypercholesterolemia, knee osteoarthritis, shoulder periarthritis, and for preventing surgical adhesion, alongside its over-the-counter (OTC) products. With a notable international footprint, Shinpoong Pharmaceutical exports its remedies to approximately 50 countries globally. This company, established in 1962, is headquartered in Seoul, South Korea.
Key people
Cheong Joo
Managing Director · since 2016
Ju Yeong Sung
Managing Director · since 2023
Hyeok Rae Kim
Assistant Managing Director · since 2018
Jae Hong Park
Assistant Managing Director
Chung Hwan Park
Assistant Managing Director
Yeong Wu Shim
Assistant Managing Director · since 2024
Yun Wuk Yang
Assistant Managing Director · since 2024
Jong Seok Yim
Assistant Managing Director
Je Man Yoo
Chief Executive Officer, Director · since 2014
Bon Jun Gu
Non-Executive Independent Director · since 2024
Jin Yeong Jung
Non-Executive Independent Director · since 2019
Dae Sin Kang
Non-Executive Independent Director · since 2024
Chan Ho Lee
Non-Executive Independent Director · since 2020
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||